|
gptkbp:instanceOf
|
gptkb:drug
Akt inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:ATCCode
|
none (investigational)
|
|
gptkbp:CASNumber
|
1032350-13-2
|
|
gptkbp:clinicalTrialPhase
|
Phase II
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:hasInChIKey
|
QJQYJZKZBZZZJY-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C25H21N5O
|
|
gptkbp:hasSMILES
|
C1CC(C1)N.C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=N2)C4=CC=CC=C4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Akt inhibitor MK-2206
|
|
gptkbp:investigatedBy
|
gptkb:cancer
colorectal cancer
prostate cancer
hematologic malignancies
|
|
gptkbp:IUPACName
|
8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one
|
|
gptkbp:mechanismOfAction
|
allosteric inhibitor of Akt
|
|
gptkbp:molecularWeight
|
391.47 g/mol
|
|
gptkbp:PubChem_CID
|
23676198
CHEMBL1172569
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:status
|
investigational drug
|
|
gptkbp:synonym
|
gptkb:MK-2206
gptkb:MK2206
|
|
gptkbp:target
|
gptkb:Akt1
gptkb:Akt2
gptkb:Akt3
|
|
gptkbp:usedIn
|
cancer research
|
|
gptkbp:bfsParent
|
gptkb:MK-2206
|
|
gptkbp:bfsLayer
|
7
|